Navigation Links
Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology
Date:12/1/2009

CAMBRIDGE, Mass., Dec. 1 /PRNewswire/ -- To address the emergence of the synthetic biology industry and to promote its potential, a group of individuals and companies announced the formation of the Synthetic Biology Industry Association (SynBIA) in Cambridge, Massachusetts last week. The goal of the association is to provide a forum for individuals and commercial interests to discuss the new industry, address its opportunities and its challenges, and advocate for its development. Founding members include representatives of febit, GENEART, Ginkgo BioWorks, Biosearch Technologies and Sutro Biopharma.

The association will serve as the trade association home for a diverse group of companies and individuals involved in synthetic biology development, including companies involved in gene synthesis, pharmaceutical development, energy development, and pollution control. The goal is to responsibly join the public discussion and promote development.

Among the more specific goals of SynBIA is an informed discussion about the risks and rewards of development. This includes participation in the discussion of dual use and in the current discussion regarding voluntary screening obligations (codes of conduct). Association members are active participants in meetings with the FBI, the National Academy of Sciences and the Association for the Advancement of Science relating to the developing synthetic biology field.

Founding Chairman JD Kittle noted, "The industry has strong potential to be a part of the solution to problems in the world's health, energy and environmental arenas. SynBIA plans to be a part of the discussion advocating for increased funding to enhance participation in these areas."

Founding Board member, Mark Waxman of Foley & Lardner, also pointed out that with the increasing visibility, IP portfolios, and transaction volume, there is a developing need for an association to address industry issues. Founding board member Frank Notka of GENEART complemented, "These industry issues have to be tackled with regard to the international character and the resulting challenges for transnational arrangements. SynBIA will through its international composition and orientation contribute to this scheme."

The SynBIA will have a collaborative relationship with the International Association of Synthetic Biology (IASB) and, through that relationship, seek to enhance international relationships developing in this field. The IASB is the international platform for synthetic biology as a field of activity. Cord F. Staehler, CEO and President of febit who is a founder and board member of both SynBIA and IASB stated, "We welcome this new addition, as it is important to have an international approach to this new and exciting industry."

For more information about SynBIA please visit www.synbia.org

For information about SynBIA please contact: jkittlejr@gmail.com

For information about IASB please contact: info@ia-sb.eu or visit www.ia-sb.eu


Contact:
Martina Schwarzkopf
Russo Partners
212-845-4292
martina.schwarzkopf@russopartnersllc.com

SOURCE Synthetic Biology Industry Association (SynBIA)


'/>"/>
SOURCE Synthetic Biology Industry Association (SynBIA)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
2. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
5. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
6. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
7. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
8. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
9. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
10. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
11. Suntech to Attend Upcoming Investor Conferences and Industry Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
Breaking Biology Technology:
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):